share_log

Baird Maintains Neutral on Mersana Therapeutics, Raises Price Target to $5

Moomoo 24/7 ·  Feb 29 07:17

Baird analyst Colleen Kusy maintains Mersana Therapeutics (NASDAQ:MRSN) with a Neutral and raises the price target from $1 to $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment